Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIM ImmunoTech Inc.AIM · Entity 8131 | Director | April 21, 2025 | April 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIM ImmunoTech Inc.
Report date April 21, 2025 · Filed April 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 521,723 |
Reported balance
After 2025-04-11 transaction · row 1
1 source rowRow 1 · 2025-04-11 · Purchase · Acquired 196,851 · Balance 521,723 F1: Shares purchased pursuant to a purchase agreement executed on April 11, 2025, but first required approval from the NYSE American which was received on April 21, 2025. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 190 |
Reported balance
Holding disclosure · report date 2025-04-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 190 |
| Common StockSEC Table I · non-derivative | Indirectby Trusts | 190 |
Reported balance
Holding disclosure · report date 2025-04-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 190 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to a purchase agreement executed on April 11, 2025, but first required approval from the NYSE American which was received on April 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2017 Filed Aug 16, 2017 17:51 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 25,953 | $0.29 Strike: $0.41 | $7,526.37 |
DisclosureSEC source: 0001613377-17-000038 · primary_doc.xml · derivative · entry 1 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,953 Underlying: Common Stock · 25,953 shares Expires 2027-08-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 17:37 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 25,284 | $0.30 Strike: $0.42 | $7,585.20 |
DisclosureSEC source: 0001613377-17-000031 · primary_doc.xml · derivative · entry 1 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,284 Underlying: Common Stock · 25,284 shares Expires 2027-07-31 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| July 15, 2017 Filed Jul 17, 2017 20:46 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 22,047 | $0.34 Strike: $0.48 | $7,495.98 |
DisclosureSEC source: 0001613377-17-000025 · primary_doc.xml · derivative · entry 1 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,047 Underlying: Common Stock · 22,047 shares Expires 2027-07-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:26 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 17,290 | $0.44 Strike: $0.49 | $7,607.60 |
DisclosureSEC source: 0001613377-17-000019 · primary_doc.xml · derivative · entry 1 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,290 Underlying: Common Stock · 17,290 shares Expires 2027-06-30 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| June 15, 2017 Filed Jun 26, 2017 20:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 17,287 | $0.44 Strike: $0.49 | $7,606.28 |
DisclosureSEC source: 0001191434-17-000001 · primary_doc.xml · derivative · entry 4 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,287 Underlying: Common Stock · 17,287 shares Expires 2027-06-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| May 31, 2017 Filed Jun 26, 2017 20:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 14,361 | $0.53 Strike: $0.59 | $7,611.33 |
DisclosureSEC source: 0001191434-17-000001 · primary_doc.xml · derivative · entry 3 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,361 Underlying: Common Stock · 14,361 shares Expires 2027-05-31 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| May 15, 2017 Filed Jun 26, 2017 20:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 13,238 | $0.57 Strike: $0.64 | $7,545.66 |
DisclosureSEC source: 0001191434-17-000001 · primary_doc.xml · derivative · entry 2 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,238 Underlying: Common Stock · 13,238 shares Expires 2027-05-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| April 30, 2017 Filed Jun 26, 2017 20:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 12,644 | $0.60 Strike: $0.67 | $7,586.40 |
DisclosureSEC source: 0001191434-17-000001 · primary_doc.xml · derivative · entry 1 MITCHELL WILLIAM M · CIK 0001191434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,644 Underlying: Common Stock · 12,644 shares Expires 2027-04-30 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.